"Tumor Stem Cell Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
| Descriptor ID |
D014410
|
| MeSH Number(s) |
E01.370.225.500.383.910 E01.370.225.500.388.930 E05.200.500.383.910 E05.200.500.388.930 E05.242.383.910 E05.242.417.500 E05.337.550.200.800
|
| Concept/Terms |
Tumor Stem Cell Assay- Tumor Stem Cell Assay
- Colony Forming Units Assay, Tumor
- Neoplasm Stem Cell Assay
- Stem Cell Assay, Tumor
- Clonogenic Cell Assay, Tumor
- Colony-Forming Units Assay, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Stem Cell Assay".
Below are MeSH descriptors whose meaning is more specific than "Tumor Stem Cell Assay".
This graph shows the total number of publications written about "Tumor Stem Cell Assay" by people in this website by year, and whether "Tumor Stem Cell Assay" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Stem Cell Assay" by people in Profiles.
-
Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging (Albany NY). 2021 07 07; 13(13):17407-17427.
-
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.
-
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med. 2017 Apr; 23(4):472-482.
-
Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan; 49(1):159-65.
-
Glycogen synthase kinase-3ß, NF-?B signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012 May 16; 104(10):749-63.
-
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer. 2012 Mar 20; 12:95.
-
Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis. 2012 Jun; 29(5):397-408.
-
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One. 2011 May 06; 6(5):e19771.
-
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9.
-
Validation of temporal optimization effects for a single fraction of radiation in vitro. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):1240-6.